These studies demonstrated the possibility of treating ALS with the viral-mediated intrathecal insertion of microRNA in patients with the mutation of SOD1, but further study would need to be done to see a clear, definite efficacy of the treatment. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.